AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9430090 — intervention group
Group type: COMPARATOR
Intervention: Increased dietary sitosterol content (three-fold) while maintaining dietary cholesterol in the homozygous and hypercholesterolemic control.
Number of subjects: 3
Study 8431334 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane in 65% nitrous oxide in oxygen
Number of subjects: 13
Study 8431334 — intervention group
Group type: COMPARATOR
Intervention: isoflurane in air and oxygen (FIO2 0.35)
Number of subjects: 13
Study 3627875 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfamil Premature with 40 mumol/dl of Tau
Number of subjects: 24
Study 3627875 — intervention group
Group type: COMPARATOR
Intervention: Enfamil Premature (unsupplemented)
Number of subjects: 24
Study 3627875 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 24
Study 30264119 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based therapy (n=255)
Number of subjects: 509
Study 30264119 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (n=254)
Number of subjects: 509
Study 27422898 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPlan1.0. (intervention group)
Number of subjects: 240
Study 27422898 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study 24996550 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 388
Study 24996550 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 388
Study 22572889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AA21004 5 mg/day
Number of subjects: 0
Study 22572889 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 0
Study 22572889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20942269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine administration (combined with intrathecal bupivacaine)
Number of subjects: 50
Study 20942269 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine alone (Control group)
Number of subjects: 50
Study 20942269 — intervention group
Group type: COMPARATOR
Intervention: Control group (Intrathecal bupivacaine alone)
Number of subjects: 50
Study 19026303 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 0
Study 19026303 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 0
Study 16140027 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bimosiamose 70 mg bid on days 1-3 and 70 mg once on the morning of day 4
Number of subjects: 12
Study 16140027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 14594033 — intervention group
Group type: EXPERIMENTAL
Intervention: HDBR exercise group (exercise with a bicycle ergometer in the supine position, 1 hour/day during bed rest)
Number of subjects: 10
Study 14594033 — intervention group
Group type: COMPARATOR
Intervention: HDBR control group (no exercise)
Number of subjects: 10
Study 10444051 — intervention group
Group type: EXPERIMENTAL
Intervention: High oxygen transmissibility (Dk/L) RGP lenses for 12 months of extended wear
Number of subjects: 411
Study 10444051 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dk lenses fitting strategy
Number of subjects: 411
Study 10444051 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients with greater corneal curvature (K) and less predicted residual astigmatism
Number of subjects: 411
Study 10444051 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for failure to adapt to RGP daily wear
Number of subjects: 411
Study 8526631 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography
Number of subjects: 685
Study 8526631 — intervention group
Group type: COMPARATOR
Intervention: Mediastinoscopy
Number of subjects: 685
Study 2801572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 2.5, 5.0, and 10.0 mg intravenous
Number of subjects: 8
Study 2801572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine after atenolol
Number of subjects: 8
Study 2801572 — intervention group
Group type: COMPARATOR
Intervention: Atenolol followed by placebo
Number of subjects: 8
Study 4271320 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with immunotherapy (multiple weekly intradermal injections of irradiated stored AML cells and Glaxo B.C.G.)
Number of subjects: 107
Study 4271320 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 107
Study 31754882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotinurad 1 mg
Number of subjects: 80
Study 31754882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotinurad 2 mg
Number of subjects: 80
Study 31754882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotinurad 4 mg
Number of subjects: 80
Study 31754882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30425011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice packs applied covering the operative forearm for 120 minutes after wound closure)
Number of subjects: 85
Study 30425011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 85
Study 30425011 — intervention group
Group type: COMPARATOR
Intervention: Control (no cryotherapy)
Number of subjects: 85
Study 28287476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice containing 409 mg total (poly)phenols
Number of subjects: 10
Study 28287476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice containing 787 mg total (poly)phenols
Number of subjects: 10
Study 28287476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice containing 1238 mg total (poly)phenols
Number of subjects: 10
Study 28287476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice containing 1534 mg total (poly)phenols
Number of subjects: 10
Study 28287476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice containing 1910 mg total (poly)phenols
Number of subjects: 10
Study 28287476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (all doses)
Number of subjects: 10
Study 25249405 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight, waist or hip circumferences, insulin levels, high triglycerides (TG), low high-density lipoprotein (HDL)
Number of subjects: 859
Study 25249405 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood sugar (FBS)
Number of subjects: 859
Study 23711600 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-PCA morphine plus intra- and postoperative ketamine and clonidine premedication (MCK)
Number of subjects: 49
Study 23711600 — intervention group
Group type: COMPARATOR
Intervention: IV-PCA morphine alone (M)
Number of subjects: 49
Study 23711600 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-PCA morphine plus oral clonidine premedication (MC)
Number of subjects: 49
Study 23711600 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-PCA morphine plus intra- and postoperative ketamine (MK)
Number of subjects: 49
Study 21263343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic nutritional fitness program for 12 weeks
Number of subjects: 75
Study 19572992 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral ampicillin (P‐Ab)
Number of subjects: 294
Study 19572992 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (O‐Ab)
Number of subjects: 294
Study 19572992 — intervention group
Group type: EXPERIMENTAL
Intervention: No antibiotic (N‐Ab)
Number of subjects: 294
Study 16680103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 25
Study 16680103 — intervention group
Group type: COMPARATOR
Intervention: Clobetasone butyrate 0.05% ointment
Number of subjects: 25
Study 15170279 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan referral
Number of subjects: 189
Study 15170279 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CT scan)
Number of subjects: 189
Study 11479164 — intervention group
Group type: EXPERIMENTAL
Intervention: Short daily hemodialysis (DHD)
Number of subjects: 12
Study 9487789 — intervention group
Group type: EXPERIMENTAL
Intervention: Female expert testimony presented prior to defendant's testimony
Number of subjects: 0
Study 9487789 — intervention group
Group type: EXPERIMENTAL
Intervention: Female expert testimony
Number of subjects: 0
Study 9487789 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert testimony presented early
Number of subjects: 0
Study 8001208 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium 0.15 mg.kg‐1 as a single bolus dose
Number of subjects: 70
Study 8001208 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium 0.015 mg.kg‐1 followed by mivacurium 0.135 mg.kg‐1
Number of subjects: 70
Study 8001208 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg.kg‐1 as a single bolus dose
Number of subjects: 70
Study 8001208 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.06 mg.kg‐1 followed by rocuronium 0.54 mg.kg‐1
Number of subjects: 70
Study 8001208 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium 0.015 mg.kg‐1 followed by rocuronium 0.54 mg.kg‐1
Number of subjects: 70
Study 8001208 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.06 mg.kg‐1 followed by mivacurium 0.135 mg.kg‐1
Number of subjects: 70
Study 8001208 — intervention group
Group type: EXPERIMENTAL
Intervention: succinylcholine 1.0 mg.kg‐1
Number of subjects: 70
Study 3511419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 98
Study 3511419 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin and Gentamicin
Number of subjects: 98
Study 30396674 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual monochromatic imaging (VMI) at 40, 50, and 60 keV
Number of subjects: 35
Study 30396674 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual monochromatic imaging (VMI)
Number of subjects: 35
Study 30396674 — intervention group
Group type: COMPARATOR
Intervention: Conventional 120 kVp images
Number of subjects: 35
Study 27936879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosclerosis
Number of subjects: 96
Study 27936879 — intervention group
Group type: COMPARATOR
Intervention: Conventional stripping
Number of subjects: 96
Study 25876346 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture and EEG biofeedback therapy (combined therapy)
Number of subjects: 100
Study 25876346 — intervention group
Group type: COMPARATOR
Intervention: EEG biofeedback therapy (control group)
Number of subjects: 100
Study 21750460 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox injection
Number of subjects: 14
Study 21750460 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine/Depomedrol injection
Number of subjects: 14
Study 20010618 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan/HCTZ 160/12.5 mg (V/HCTZ)
Number of subjects: 648
Study 20010618 — intervention group
Group type: COMPARATOR
Intervention: valsartan 80 mg (V-low)
Number of subjects: 648
Study 20010618 — intervention group
Group type: COMPARATOR
Intervention: valsartan 160 mg (V-high)
Number of subjects: 648
Study 19186332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance Dance Revolution (DDR)
Number of subjects: 60
Study 19186332 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 60
Study 19186332 — intervention group
Group type: EXPERIMENTAL
Intervention: DDR
Number of subjects: 60
Study 18435564 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 18435564 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study 15239261 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-lipiodol emulsion
Number of subjects: 65
Study 15239261 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin-lipiodol emulsion
Number of subjects: 65
Study 11739221 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical medication review by a pharmacist
Number of subjects: 1188
Study 11739221 — intervention group
Group type: COMPARATOR
Intervention: Normal general practice review
Number of subjects: 1188
Study 9240887 — intervention group
Group type: COMPARATOR
Intervention: Gastrin levels before NEC
Number of subjects: 14
Study 9240887 — intervention group
Group type: COMPARATOR
Intervention: Gastrin levels after NEC
Number of subjects: 14
Study 9240887 — intervention group
Group type: COMPARATOR
Intervention: Neurotensin levels after NEC
Number of subjects: 14
Study 9240887 — intervention group
Group type: COMPARATOR
Intervention: VIP values before NEC
Number of subjects: 14
Study 9240887 — intervention group
Group type: COMPARATOR
Intervention: VIP values after NEC
Number of subjects: 14
Study 8318484 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microliters microdrops of cyclopentolate 0.5% and phenylephrine 2.5%
Number of subjects: 26
Study 8318484 — intervention group
Group type: COMPARATOR
Intervention: Standard 26 microliters eye drops of cyclopentolate 0.5% and phenylephrine 2.5%
Number of subjects: 26
Study 3704898 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous drains
Number of subjects: 0
Study 3704898 — intervention group
Group type: COMPARATOR
Intervention: Stay suture closure
Number of subjects: 0
Study 31529406 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 25 mg
Number of subjects: 24
Study 31529406 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Number of subjects: 24
Study 31529406 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Number of subjects: 24
Study 31529406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31529406 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept (all doses)
Number of subjects: 24
Study 30481790 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic insert Mydriasert®
Number of subjects: 80
Study 30481790 — intervention group
Group type: COMPARATOR
Intervention: Eye drops (2.5% phenylephrine and 0.5% tropicamide)
Number of subjects: 80
Study 26094972 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 /0.077% NaF dentifrice
Number of subjects: 36
Study 26094972 — intervention group
Group type: COMPARATOR
Intervention: 0.32% NaF/0.3% triclosan dentifrice
Number of subjects: 36
Study 24972663 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Based Method groups (PBM)
Number of subjects: 50
Study 24972663 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 50
Study 24437167 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual dose of nitrates (nitroglycerin and mononitrate isosorbide)
Number of subjects: 41
Study 21500886 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-session group coping skills intervention targeting personality risk factors
Number of subjects: 364
Study 21500886 — intervention group
Group type: COMPARATOR
Intervention: Control no-intervention condition
Number of subjects: 364
Study 19633827 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering treatment with perindopril-indapamide (n = 623)
Number of subjects: 1602
Study 19633827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control targeting HbA(1c) of < or = 6.5% (n = 630)
Number of subjects: 1602
Study 19633827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 618)
Number of subjects: 1602
Study 19633827 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control (n = 611)
Number of subjects: 1602
Study 17086852 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositioning appliance (REPOS)
Number of subjects: 33
Study 17086852 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-repositioning appliance (NONREPOS)
Number of subjects: 33
Study 15582060 — intervention group
Group type: EXPERIMENTAL
Intervention: Money to households
Number of subjects: 5600
Study 15582060 — intervention group
Group type: COMPARATOR
Intervention: Resources to local health teams
Number of subjects: 5600
Study 15582060 — intervention group
Group type: EXPERIMENTAL
Intervention: Both packages
Number of subjects: 5600
Study 15582060 — intervention group
Group type: COMPARATOR
Intervention: Neither
Number of subjects: 5600
Study 11303848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 50 mg/kg/dose administered every 8 to 12 hours
Number of subjects: 259
Study 11303848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 259
Study 11303848 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime, Cefotaxime, Cefuroxime (comparator therapy)
Number of subjects: 259
Study 8990415 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet ad libitum
Number of subjects: 58
Study 8990415 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate, unsupervised exercise
Number of subjects: 58
Study 8990415 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained weight)
Number of subjects: 58
Study 8491068 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren (intravenous) at doses of 10, 20, 40, 80, 160, and 320 mg
Number of subjects: 9
Study 8491068 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren (oral) at doses of 100, 200, 400, 800, and 1600 mg
Number of subjects: 9
Study 8491068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8491068 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren (oral) at 1600 mg
Number of subjects: 9
Study 3329766 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT) 655 mg
Number of subjects: 12
Study 3329766 — intervention group
Group type: COMPARATOR
Intervention: Acetyl salicylic acid (ASA) 652 mg
Number of subjects: 12
Study 30074156 — intervention group
Group type: EXPERIMENTAL
Intervention: New nano-film single-rivet occluders
Number of subjects: 23
Study 30074156 — intervention group
Group type: COMPARATOR
Intervention: Traditional occluders (Control)
Number of subjects: 23
Study 26684923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose buprenorphine (initial dosage 0.1 mg once or twice daily; mean final dosage 0.44 mg/day)
Number of subjects: 62
Study 26684923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 24441865 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing (OD) of amikacin (15 or 20 mg/kg)
Number of subjects: 31
Study 24441865 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily dosing (TD) of amikacin (15 or 20 mg/kg)
Number of subjects: 31
Study 24441865 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin pharmacokinetics
Number of subjects: 31
Study 24441865 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin dosing based on neonatal age
Number of subjects: 31
Study 22251022 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to different SSRI
Number of subjects: 0
Study 22251022 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to an alternate antidepressant (venlafaxine)
Number of subjects: 0
Study 22251022 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to an alternate SSRI plus cognitive behavior therapy (CBT)
Number of subjects: 0
Study 22251022 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to venlafaxine plus CBT
Number of subjects: 0
Study 20016124 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive training (self-testing strategy)
Number of subjects: 56
Study 20016124 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 56
Study 18534618 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled CO2 (0.8%) for 2 hours
Number of subjects: 42
Study 18534618 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline for 2 hours
Number of subjects: 42
Study 18534618 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 42
Study 15668285 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly irinotecan at a dose of 70 mg/m(2) days 1, 8, 15, 22, 29 in combination with capecitabine 1000 mg/m(2) twice daily days 1-14 and days 22-35 every 6 weeks (arm A)
Number of subjects: 75
Study 15668285 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-weekly irinotecan at a dose of 300/240 mg/m(2) day 1 and days 22 in combination with capecitabine 1000 mg/m(2) twice daily days 1-14 and days 22-35 every 6 weeks (arm B)
Number of subjects: 75
Study 15668285 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective tumor response
Number of subjects: 75
Study 11868796 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lormetazepam
Number of subjects: 0
Study 11868796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10907738 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol
Number of subjects: 0
Study 10907738 — intervention group
Group type: COMPARATOR
Intervention: SSRI
Number of subjects: 0
Study 7785682 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.125% verapamil
Number of subjects: 10
Study 7785682 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.25% verapamil
Number of subjects: 10
Study 7785682 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 10
Study 2366025 — intervention group
Group type: EXPERIMENTAL
Intervention: M.R.I. (Magnetic Resonance Imaging)
Number of subjects: 9
Study 25076 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.01 mg kg‐1
Number of subjects: 92
Study 25076 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.02 mg kg‐1
Number of subjects: 92
Study 25076 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0.125 mg kg‐1
Number of subjects: 92
Study 25076 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0.25 mg kg‐1
Number of subjects: 92
Study 25076 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam double dose
Number of subjects: 92
Study 25076 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam larger doses
Number of subjects: 92
Study 25076 — intervention group
Group type: COMPARATOR
Intervention: Diazepam larger doses
Number of subjects: 92
Study 31882564 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental DNA methylation markers
Number of subjects: 430
Study 31882564 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternally imprinted gene DLGAP2
Number of subjects: 430
Study 30294825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-containing juice (n = 40)
Number of subjects: 105
Study 30294825 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (n = 44)
Number of subjects: 105
Study 30294825 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin (n = 43)
Number of subjects: 105